| 前收市價 | 29.06 |
| 開市 | 29.14 |
| 買盤 | 28.52 x 27000 |
| 賣出價 | 28.54 x 35000 |
| 今日波幅 | 28.42 - 29.21 |
| 52 週波幅 | 25.42 - 53.45 |
| 成交量 | |
| 平均成交量 | 1,774 |
| 市值 | 無 |
| Beta 值 (5 年，每月) | 無 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | 無 |
| 業績公佈日 | 2024年8月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
ReutersJudge cuts Bayer $2.25 billion Roundup verdict to $400 million
NEW YORK (Reuters) -A Pennsylvania judge on Tuesday slashed a $2.25 billion U.S. verdict against Bayer to $400 million for a Pennsylvania man who said he developed cancer from exposure to the company's Roundup weedkiller. A jury in the Philadelphia Court of Common Pleas found that John McKivison's non-Hodgkins lymphoma was the result of using Roundup for yard work at his house for several years, and it ordered Bayer to pay $250 million in compensatory damages and $2 billion in punitive damages. Judge Susan Schulman granted some of Bayer's post-trial motions challenging that verdict, reducing compensatory damages to $50 million and punitive damages to $350 million.
BloombergBayer Calls Roundup Suits Existential Threat to Company, Farming
(Bloomberg) -- Bayer AG Chief Executive Officer Bill Anderson said the wave of lawsuits over its Roundup weedkiller is an “existential” threat to the company and farmers, ratcheting up the stakes as it considers a controversial legal maneuver.Most Read from BloombergSingapore Air Changes Seatbelt Rules After Fatal TurbulenceSpaceX Weighs Plan to Sell Shares at $200 Billion ValuationThe Rise and Fall of Simon Sadler's Segantii, One of Asia's Most Successful Hedge FundsChina’s $538 Billion Deposit
BenzingaBayer Highlights Detailed Data From Twin Late-Stage Trials On Experimental Menopause Candidate, Seeks Regulatory Approval
Bayer AG (OTC:BAYRY) (OTC:BAYZF) will present detailed results from the Phase 3 studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms (hot flashes) associated with menopause compared to placebo. The company released the topline data showing elinzanetant met all four primary endpoints in both studies. These data will be presented at the 2024 American College of Obstetricians and Gynec
